Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Myriad Genetics Inc MYGN

Healthcare Biotechnology
Myriad Genetics, Inc. is a genetic testing and precision medicine company. The Company develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. The Company is focused on three key areas where it has... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:MYGN)

Myriad Genetics Showcases New Research and Product Innovations Advancing Cancer Care at 2024 ASCO® Annual Meeting

GlobeNewswire 2 days ago

New Study Published in JCO Precision Oncology Shows Myriad Genetics' Prolaris Test Can Predict Benefit of Hormone Therapy Treatment in Men with Localized Prostate Cancer

GlobeNewswire 9 days ago

Myriad Genetics Reports Strong First Quarter 2024 Financial Results; Achieves 12% Revenue Growth Year-Over-Year; Significantly Improved Year-Over-Year Net Loss and Generated Positive Adjusted EBITDA

GlobeNewswire May 7, 2024

Myriad Genetics Announces Reorganization of European Operations and Sale of EndoPredict Business

GlobeNewswire May 7, 2024

Myriad Genetics to Release First Quarter 2024 Financial Results on May 7, 2024

GlobeNewswire April 30, 2024

Nearly Half of Americans Say They've Lost Time in Their Lives Due to Poor Mental Health, According to the GeneSight Mental Health Monitor

GlobeNewswire April 17, 2024

New Myriad Genetics Study Published in Prenatal Diagnosis Shows High Positive Predictive Value for 22q11.2 Microdeletion Syndrome Using Prequel® Prenatal Screen

GlobeNewswire April 16, 2024

Myriad Genetics Research Shows Reduction in Hospitalizations for Patients with Depression after GeneSight Testing

GlobeNewswire April 9, 2024

Myriad Genetics Announces Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date

GlobeNewswire March 21, 2024
View More News ››

Opinion & Analysis (NDAQ:MYGN)

Myriad Genetics Shares Fall 30% on Q2 Earnings and Executive Leadership Change

Streetwise Reports February 10, 2020

This company's loss is your gain

Marc Lichtenfeld June 19, 2013

Stock pick in cancer genetics testing

Michael Cintolo December 23, 2008
View More Opinion ››

Bullboard Posts (NDAQ:MYGN)

4 STOCKS OPENING NEW FRONTIERS IN WOMEN’S HEALTH!

$MYGN $SERA $PGNY $MYOV   8th March celebrates the cultural, political and socioeconomic achievements of women ...
AviseAnalytics - March 8, 2022

Myriad Genetics Inc. Options

On 01/12/09 Myriad Genetics Inc. options ( MYGN ) are used as an example of market neutral investing on PERSONALHEDGEFUNDS.COM. Hedge...
nickmessaro02 - January 10, 2009

MYGN is seen possible buy by Chartplays.com

MYGN is reviewed as the focus free chart of the day at Chartplays.com today. According to the folks at Chartplays.com, MYGN is showing...
battlinal74 - August 16, 2002

Target Acquire Price $16

Anyone have any opinions? Great balance sheet, but drastically overpriced.
0379 - May 7, 2002

Genomics Execs Aren’t Worried

Ignore the bears, genomics bulls say. Advancements in medicine are coming and companies that understand genes are the ones that will make...
SCCNewsServices - April 17, 2000
View more Bullboard ››

Visionstate Corp.

Visionstate Corp.

Visionstate Corp. is a growth-oriented company that invests in the research and development of the Internet of Things, big ...
View More »